James L. Gulley Explained

James L. Gulley
Profession:Medical oncologist
Specialism:genitourinary oncology, immunotherapy
Research Field:cancer research
Education:Loma Linda University, Emory University, National Cancer Institute
Work Institutions:National Cancer Institute

James L. Gulley is an American cancer researcher and the Director of the Medical Oncology Service at National Cancer Institute.[1]

Early life and education

He graduated from Loma Linda University, California[2] and his M.D./Ph.D. Medical Scientist Training Program, at National Institutes of Health (NIH) and his dissertation on tumor immunology.[3] Later, Gulley did his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship at the NCI.[4]

Research and career

Gulley did his research in immunotherapy for prostate cancer. His studies involved the use of cancer vaccine[5] and immune checkpoint inhibitors or other strategies to enhance vaccine-mediated killing.[6] Since 1999, he ran clinical trials at the NCI,[7] serving as Principal Investigator or an Associate Investigator on approximately 40 trials. He is also running studies on cancer patients.[8] [9] [10]

Publications

He published over 250 research papers & book chapters across leading journals.[11] [12] Some of his notable publications are listed below:

FDA approval

At the 2010 ASCO meeting Gulley and his group reported on the use of Ipilimumab with a vector-based vaccine for treating advanced prostate cancer. This phase I trial using PSA-TRICOM with Ipilimumab (Ipi) showed promise for Overall Survival (OS).[21] Ipi is used in melanoma vaccine clinical trials.[22] It was approved by the FDA in March 2011.[23] [24] [25] [26]

Awards

External links

Notes and References

  1. Web site: Medical Oncology Service. 2016-02-09. Center for Cancer Research. en. 2019-08-22.
  2. Web site: James L. Gulley, M.D., Ph.D.. 2014-08-12. Center for Cancer Research. en. 2019-11-16.
  3. Web site: Principal Investigators. NIH Intramural Research Program. en. 2019-08-06.
  4. Web site: Medical Oncology Web - FELLOWSHIP. Medicaloncology.cancer.gov. 2010-07-14.
  5. Gulley. James L.. Arlen. Philip M.. Schlom. Jeffrey. 2007-07-01. Cancer Vaccines: Moving Beyond Current Paradigms. Clinical Cancer Research. en. 13. 13. 3776–3782. 10.1158/1078-0432.CCR-07-0588. 1078-0432. 17606707. 2536755.
  6. Web site: James L. Gulley, MD, PhD, on Prostate Cancer: Expanding Immunotherapy Options - The ASCO Post. ascopost.com. 2019-08-22.
  7. Web site: James Gulley. Gulley. James. 2015-02-23. NIH Intramural Research Program. en. 2019-11-16.
  8. Web site: Clinical Trials at NIH: Health Care Professionals: Investigator Profiles: James L. Gulley, M.D. Bethesdatrials.cancer.gov. https://web.archive.org/web/20100527113440/http://bethesdatrials.cancer.gov/investigator-profiles/gulley/default.asp. 2010-05-27. dead. 2010-07-14.
  9. Web site: Clinical Trials at NIH: Health Care Professionals: Investigator Profiles: James L. Gulley, M.D.. https://web.archive.org/web/20100527113440/http://bethesdatrials.cancer.gov/investigator-profiles/gulley/default.asp. dead. 2010-05-27. 2010-05-27. 2019-08-22.
  10. Web site: Genitourinary Malignancies Branch Clinical Trials. Center for Cancer Research. en. 2019-08-22.
  11. Web site: My Bibliography James Gulley's Bibliography.
  12. Web site: Center for Cancer Research - Staff Pages. Ccr.cancer.gov. https://web.archive.org/web/20100527145339/http://ccr.cancer.gov/staff/cv.asp?profileid=5686. 2010-05-27. dead. 2010-07-14.
  13. Kantoff. Philip W.. Schuetz. Thomas J.. Blumenstein. Brent A.. Glode. L. Michael. Bilhartz. David L.. Wyand. Michael. Manson. Kelledy. Panicali. Dennis L.. Laus. Reiner. 2010-03-01. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 28. 7. 1099–1105. 10.1200/JCO.2009.25.0597. 1527-7755. 2834462. 20100959.
  14. Dahut. William L.. Gulley. James L.. Sharifi. Nima. 2005-07-13. Androgen Deprivation Therapy for Prostate Cancer. JAMA. en. 294. 2. 238–244. 10.1001/jama.294.2.238. 16014598. 0098-7484. free.
  15. Dahut. William L.. Gulley. James L.. Arlen. Philip M.. Liu. Yinong. Fedenko. Katherine M.. Steinberg. Seth M.. Wright. John J.. Parnes. Howard. Chen. Clara C.. 2004-07-01. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Journal of Clinical Oncology. 22. 13. 2532–2539. 10.1200/JCO.2004.05.074. 0732-183X. 15226321. free.
  16. Gulley. James L.. Arlen. Philip M.. Bastian. Anne. Morin. Steven. Marte. Jennifer. Beetham. Patricia. Tsang. Kwong-Yok. Yokokawa. Junko. Hodge. James W.. 2005-05-01. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clinical Cancer Research. 11. 9. 3353–3362. 10.1158/1078-0432.CCR-04-2062. 1078-0432. 15867235. free.
  17. Marshall. John L.. Gulley. James L.. Arlen. Philip M.. Beetham. Patricia K.. Tsang. Kwong-Yok. Slack. Rebecca. Hodge. James W.. Doren. Sandra. Grosenbach. Douglas W.. 2005-02-01. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. Journal of Clinical Oncology. 23. 4. 720–731. 10.1200/JCO.2005.10.206. 0732-183X. 15613691.
  18. Arlen. Philip M.. Gulley. James L.. Parker. Catherine. Skarupa. Lisa. Pazdur. Mary. Panicali. Dennis. Beetham. Patricia. Tsang. Kwong Y.. Grosenbach. Douglas W.. 2006-02-15. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clinical Cancer Research. 12. 4. 1260–1269. 10.1158/1078-0432.CCR-05-2059. 1078-0432. 1526707. 16489082.
  19. Gulley. James L.. Arlen. Philip M.. Madan. Ravi A.. Tsang. Kwong-Yok. Pazdur. Mary P.. Skarupa. Lisa. Jones. Jacquin L.. Poole. Diane J.. Higgins. Jack P.. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunology, Immunotherapy . 59. 5. 663–674. 10.1007/s00262-009-0782-8. 1432-0851. 2832083. 19890632. 2010.
  20. Madan. Ravi A.. Mohebtash. Mahsa. Arlen. Philip M.. Vergati. Matteo. Rauckhorst. Myrna. Steinberg. Seth M.. Tsang. Kwong Y.. Poole. Diane J.. Parnes. Howard L.. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. The Lancet. Oncology. 13. 5. 501–508. 10.1016/S1470-2045(12)70006-2. 1474-5488. 6359905. 22326924. 2012.
  21. Madan. Ravi A.. Mohebtash. Mahsa. Arlen. Philip M.. Vergati. Matteo. Rauckhorst. Myrna. Steinberg. Seth M.. Tsang. Kwong Y.. Poole. Diane J.. Parnes. Howard L.. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. The Lancet. Oncology. 13. 5. 501–508. 10.1016/S1470-2045(12)70006-2. 1474-5488. 6359905. 22326924. 2012.
  22. 10.1158/1078-0432.CCR-10-2463 . Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma . 2010 . Sarnaik . A. A. . Yu . B. . Yu . D. . Morelli . D. . Hall . M. . Bogle . D. . Yan . L. . Targan . S. . Solomon . J. . Nichol . G. . Yellin . M. . Weber . J. S. . Clinical Cancer Research . 17 . 4 . 896–906 . 21106722 . 3041838. 8 .
  23. 10.1053/j.seminoncol.2010.09.015 . Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy . 2010 . Hoos . Axel . Ibrahim . Ramy . Korman . Alan . Abdallah . Kald . Berman . David . Shahabi . Vafa . Chin . Kevin . Canetta . Renzo . Humphrey . Rachel . Seminars in Oncology . 37 . 5 . 533–46 . 21074069 . free .
  24. Web site: Experimental Drug Improves Survival in Advanced Melanoma - National Cancer Institute . www.cancer.gov . dead . https://web.archive.org/web/20100811020701/http://www.cancer.gov/clinicaltrials/results/ipilimumab0610 . 2010-08-11.
  25. Madan. Ravi A.. Mohebtash. Mahsa. Arlen. Philip M.. Vergati. Matteo. Rauckhorst. Myrna. Steinberg. Seth M.. Tsang. Kwong Y.. Poole. Diane J.. Parnes. Howard L.. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. The Lancet. Oncology. 13. 5. 501–508. 10.1016/S1470-2045(12)70006-2. 1474-5488. 6359905. 22326924. 2012.
  26. Schlom. Jeffrey. Gulley. James L.. 2018-12-04. Vaccines as an Integral Component of Cancer Immunotherapy. JAMA. 320. 21. 2195–2196. 10.1001/jama.2018.9511. 1538-3598. 6538063. 30419097.
  27. Web site: President Obama Honors Outstanding Early-Career Scientists. 2011-09-26. whitehouse.gov. en. 2019-08-22.
  28. Web site: CCR Connections (News) - An Early Career Off to a Stellar Start. home.ccr.cancer.gov. 2019-08-22.
  29. Web site: Recent CCR Awards. 2016-06-21. Center for Cancer Research. en. 2019-08-22.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "James L. Gulley".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.